GlassScriptPhysician profile
Jeffrey Reisert
NPI 1780668350
$516.15
in general payments reported to CMS, 2019-2025
12 companies · $202 in 2025
The $202 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39.59 · 2023: $251 · 2024: $22.79 · 2025: $202.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $477.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $476.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Perspectum Diagnostics LTD | $133.67 | 2023 | Livermultiscan |
| Daiichi Sankyo INC. | $117.63 | 2023 | |
| Astellas Pharma US INC | $39.59 | 2019 | |
| Abbvie INC. | $39.19 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $38.57 | 2025 | Trintellix |
| Novo Nordisk INC | $29.45 | 2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $24.06 | 2025 | Zepbound |
| Sanofi-Aventis U.S. LLC | $22.79 | 2024 | |
| Medtronic, INC. | $21.68 | 2025 | Minimed 780g |
| Philips North America LLC | $21.24 | 2025 | Vest Therapy Und |
| Exact Sciences Corporation | $14.20 | 2025 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.08 | 2025 | Caplyta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Reisert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.